Subscribe free

HPB & Spleen ·

Reassessing Malignancy Risks in Mixed-Type IPMNs

Mixed-type intraductal papillary mucinous neoplasms (IPMNs) have a lower malignancy risk than previously thought, affecting surgical decision-making.

  • 46.5% of mixed-IPMNs showed malignancy, compared to 79.2% in main-duct and 33.9% in branch-duct IPMNs.
  • In the absence of high-risk features, the malignancy rate for mixed-IPMNs dropped to 24.7%, similar to branch-duct IPMNs at 20.2%.

Consider patient selection carefully, as many mixed-IPMNs may be benign based on final pathology results.

  • One-third of mixed-IPMNs had no main pancreatic duct involvement, challenging existing risk stratification.

Journal Article by De Stefano F, Fagenholz P (…) Castillo CF et 9 al. in Ann Surg

Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.

read the whole article in Ann Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →